
Featured Article

Neurosurgery in Parkinson Disease: A Brief History and Look Forward
Although deep brain stimulation, similar to all Parkinson disease therapies, cannot cure, modify, or slow progression of the disease, some recent research suggests that the symptom alleviation and quality-of-life improvement it provides might lead to mild improvements in longevity.
Latest

AAN: Occupational Exposure to Diesel Exhaust Tied to ALS Risk
Researchers found that for men with any occupational exposure to diesel exhaust, the odds ratio for amyotrophic lateral sclerosis increased with increasing lag periods.

AAN: Alpha-Synuclein Levels in Tears May Help ID Parkinson's
Researchers say that tears may be an inexpensive, reliable, and noninvasive biological marker of Parkinson's disease.

Connection Between Essential Tremor, Depression Remains Unclear
Approximately 20% of patients in this cohort were considered clinically depressed based on GDS criteria.

Demoralization Common in Patients With Parkinson Disease
Demoralization is common in patients with Parkinson disease and is associated with motor dysfunction.

Extended Release Amantadine Effective for Reducing Dyskinesia in Parkinson Disease
ADS-5102 is a promising treatment option: if taken once daily at night, it achieves highest plasma drug concentrations throughout the day when symptoms are most bothersome.

Pseudobulbar Affect Linked to Mood Symptoms in Parkinsonian Syndromes
Pseudobulbar affect is characterized by episodes of inappropriate laughing or crying, and may be associated with increased anxiety and depression, as well as lower mental health status.

Progressive Supranuclear Palsy: Pedunculopontine Nucleus DBS May Not Improve Symptoms
Seven patients with progressive supranuclear palsy received bilateral pedunculopontine nucleus deep brain stimulation at frequencies of 8, 20, 60, and 130 Hz.

Montreal Parkinson Risk of Dementia Scale Deemed Accurate
The office-based, eight-item Montreal Parkinson Risk of Dementia Scale is a valid predictor of development of dementia.

Riluzole Prolongs Survival in Late-Stage Amyotrophic Lateral Sclerosis
Patients who received 100 mg/day riluzole spent significantly more time in stage 4 than patients who were randomly assigned to placebo.

NDA Submitted for Sublingual Film to Treat OFF Episodes in Parkinson's Disease
Sunovion announced the submission of its New Drug Application for apomorphine sublingual film for OFF episodes linked with PD.
Neurology Advisor Articles
- The Consequences of Compensation in Autism
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Demoralization Common in Patients With Parkinson Disease
- Connection Between Essential Tremor, Depression Remains Unclear
- American Academy of Neurology Annual Meeting 2018: What to Expect
- Palliative Care in Movement Disorders: Recommendations for Improvement
- The Symbiosis of Headache and Sleep
- Assessing and Treating Cognitive, Mood Impairments in Patients With Stroke
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Headache in Older Adults: Unique Causes and Treatments
- AAN: High Fish Intake Linked to Reduced Risk of Multiple Sclerosis
- AAN: Gluten-Free Diet May Help Cut Pain in Gluten Neuropathy
- AAN: Occupational Exposure to Diesel Exhaust Tied to ALS Risk
- AAN: Adherence to DASH Diet May Reduce Risk of Depression
- AAN: Alpha-Synuclein Levels in Tears May Help ID Parkinson's